PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
 
Antimicrob Agents Chemother. 2010 January; 54(1): 533–535.
Published online 2009 November 2. doi:  10.1128/AAC.00859-09
PMCID: PMC2798549

BEL-2, an Extended-Spectrum β-Lactamase with Increased Activity toward Expanded-Spectrum Cephalosporins in Pseudomonas aeruginosa[down-pointing small open triangle]

Abstract

A Pseudomonas aeruginosa isolate recovered in Belgium produced a novel extended-spectrum ß-lactamase, BEL-2, differing from BEL-1 by a single Leu162Phe substitution. That modification significantly altered the kinetic properties of the enzyme, increasing its affinity for expanded-spectrum cephalosporins. The blaBEL-2 gene was identified from a P. aeruginosa isolate clonally related to another blaBEL-1-positive isolate.

Extended-spectrum ß-lactamases (ESBLs), such as TEM, SHV, PER, VEB, GES, and more recently, CTX-M variants, are reported increasingly to be found in Pseudomonas aeruginosa in various areas (1, 2, 7, 8, 10-12, 15, 17, 21, 23, 27, 28, 30). The BEL-1 ß-lactamase, distantly related to other ESBLs, was identified from a P. aeruginosa isolate from Roeselare, Belgium, which interestingly shows resistance to ticarcillin and ceftazidime but only reduced susceptibility to piperacillin, cefepime, cefpirome, and aztreonam (24). The blaBEL-1 determinant was found as a gene cassette in the chromosome-borne class 1 integron, In120, that includes other resistance genes (aacA4, aadA5, and smr2) and that was part of a Tn1404-type transposon structure (24). Very recently, Bogaerts et al. (5) reported on the diffusion of BEL-1-producing isolates in various hospital centers of Belgium and also found that BEL-1 could be associated with other relevant β-lactamases, such as the VIM-1 metallo-β-lactamase (5).

P. aeruginosa isolate 531 (this study) was recovered from a urine sample of a patient hospitalized in Roeselare, Belgium, in February 2007 for pneumonia and was resistant to all β-lactams but imipenem (Table (Table1).1). A synergy between aztreonam or ceftazidime and clavulanic acid-containing disks suggested the synthesis of an ESBL (19). PCR followed by sequencing using ESBL gene-specific primers (24) identified a novel gene encoding BEL-2, which differs from BEL-1 by a single amino acid substitution (Leu to Phe at Ambler position 162) (3). Transfer of a ß-lactam resistance marker from P. aeruginosa 531 to Escherichia coli or to P. aeruginosa reference strains was unsuccessful by either conjugation or transformation (25). Plasmid extraction performed as described previously (14) did not identify any plasmid, suggesting a chromosomal location of the blaBEL-2-like gene in P. aeruginosa 531. A pulsed-field gel electrophoresis (PFGE) analysis (4) showed that isolates 531 (BEL-2 positive) and 51170 (BEL-1 positive), recovered from the same geographical area, were clonally related. A PCR mapping approach confirmed the presence of a class 1 integron whose structure was identical to that of In120 of P. aeruginosa 51170 (24) and identified an identical structure in P. aeruginosa 531 (data not shown). Overall, these data suggest that the blaBEL-2 sequence likely resulted from a mutational event that had occurred in In120-carrying P. aeruginosa strains.

TABLE 1.
MICs of β-lactamsa

In order to compare the contributions of BEL-1 and BEL-2 to ß-lactam resistance, the corresponding genes (amplified using primers PreBEL-A [5′-AGACGTAAGCCTATAATCTC] and PreBEL-B [5′-GCGAATTGTTAGACGTATG]) were cloned in the pCR-BluntII-TOPO vector (Invitrogen, Cergy-Pontoise, France) and subsequently introduced into E. coli TOP10, giving rise to recombinant strains E. coli TOP10(pSB-1) and E. coli TOP10(pSB-2), producing BEL-1 and BEL-2, respectively. MICs of ß-lactams were determined by solid agar dilutions following the guidelines of the CLSI (9). E. coli TOP10(pSB-2) had MICs of piperacillin, cephalothin, and cefuroxime that were lower than those of E. coli TOP10(pSB-1), but its cefotaxime, ceftazidime, ceftriaxone, and cefepime MICs were higher than those of TOP10(pSB-1), while MICs of carbapenems were the same (Table (Table11).

E. coli TOP10(pSB-2) produced a ß-lactamase with a pI value of 7.1 (identical to that of BEL-1) (18). Approximately 1.5 mg of BEL-2 was purified (>95% as estimated by SDS-PAGE analysis; data not shown) from an E. coli MCT236(pET-BEL-2) crude extract by using a two-step chromatography process (an anion exchange at pH 7.5 using a Q Sepharose Fast Flow column followed by a cation exchange at pH 6.2 using a 1-ml Resource S column). (The specific activity was 8,800 nmol/min·mg of protein with 100 μM of cephalothin as the substrate, purified 95-fold.) BEL-2 had a broad-spectrum hydrolysis profile, including penicillins and expanded-spectrum cephalosporins but not cephamycins and carbapenems (Table (Table2).2). BEL-2 overall showed higher catalytic efficiencies (kcat/Km) than BEL-1 for aztreonam and most oxyiminocephalosporins (cefotaxime, ceftazidime, ceftriaxone, and cefepime but not cefuroxime). This was due to a significant alteration of the Km values for these substrates with BEL-2, which were decreased relative to those of BEL-1 by 300-fold (ceftriaxone) to up to three orders of magnitude (ceftazidime) (Table (Table2).2). Interestingly, a decrease of the Km value was also observed with all the other substrates (though the variation was less important), likely reflecting a modification of the active site structure and thus substrate recognition. Overall, BEL-2 kcat values were also lower but to a lesser extent (Table (Table2).2). The values of catalytic efficiency toward expanded-spectrum cephalosporins for BEL-2 may explain the higher MICs observed for the BEL-2-producing recombinant E. coli strains and P. aeruginosa clinical isolate. Position 162 is located at the beginning of the Ω loop, which bears the functionally important Glu166 residue, which is conserved in class A enzymes, and where mutations conferring extended-spectrum properties have been extensively reported in natural TEM and SHV variants (13). The presence of a bulky Phe residue in BEL-2 might modify the orientation of the Ω loop and the overall geometry of the active site. The further extension of the substrate profile as a consequence of a single substitution in the Ω loop observed with the BEL-2 variant may parallel that of other enzymes, e.g., CTX-M-19 (CTX-M-14 Pro167Ser variant) (26) or GES-2 (GES-1 Gly170Asn variant) (28). Inhibition studies showed that BEL-2 and BEL-1 are similarly inhibited by clavulanic acid, tazobactam, and sulbactam (50% inhibitory concentrations of 0.1, 2, and 3 μM, respectively).

TABLE 2.
Kinetic parameters of purified ß-lactamase BEL-2, in comparison with previously reported values of BEL-1 (22)a

Conclusion.

This study emphasizes the spread and evolution of BEL-type ESBLs in P. aeruginosa in Belgium. A novel integron-encoded BEL-type ß-lactamase with enhanced hydrolytic properties was identified. This evolution of an ESBL determinant expressed in a P. aeruginosa strain is similar to that reported for GES-1 in South Africa, where P. aeruginosa isolates expressing ESBL GES-2 or GES-5 with expanded-spectrum activities toward carbapenems have been reported (16, 29), and also in Brazil, where clonally related P. aeruginosa isolates expressing either GES-1 or GES-5 coexist (22).

It is tempting to hypothesize that a BEL-2 producer has been selected under antibiotic selective pressure and especially by expanded-spectrum cephalosporins. This work shows that ESBL BEL-1 has the potential to evolve with significantly altered biochemical properties. It remains to evaluate whether BEL-type ß-lactamases could further evolve to gain activity on cephamycins and/or carbapenems (as observed for several GES-type ESBLs [20]) or resistance to ß-lactamase inhibitors (as observed for several TEM and SHV variants [6]).

Nucleotide sequence accession number.

The nucleotide and protein sequences corresponding to the BEL-2 enzyme have been registered in GenBank under accession number FJ666063.

Acknowledgments

This work was funded by a grant from the Ministère de l'Education Nationale et de la Recherche (UPRES-EA3539), Université Paris XI, France, mostly by grants from the European Community (DRESP2 [LSHM-CT-2005-018705] and TROCAR [HEALTH-F3-2008-223031]), and by INSERM.

We thank S. Bernabeu for technical assistance.

Footnotes

[down-pointing small open triangle]Published ahead of print on 2 November 2009.

REFERENCES

1. Aktas, Z., L. Poirel, M. Salcioğlu, P. E. Ozcan, K. Midilli, C. Bal, O. Anğ, and P. Nordmann. 2005. PER-1- and OXA-10-like ß-lactamases in ceftazidime-resistant Pseudomonas aeruginosa isolates from intensive care unit patients in Istanbul, Turkey. Clin. Microbiol. Infect. 11:193-198. [PubMed]
2. al Naiemi, N., B. Duim, and A. Bart. 2006. A CTX-M extended-spectrum ß-lactamase in Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J. Med. Microbiol. 55:1607-1608. [PubMed]
3. Ambler, R. P., A. F. W. Coulson, J.-M. Frère, J. M. Ghuysen, B. Joris, M. Forsman, R. C. Levesque, G. Tiraby, and S. G. Waley. 1991. A standard numbering scheme for the class A ß-lactamases. Biochem. J. 276:269-270. [PubMed]
4. Aubron, C., L. Poirel, N. Fortineau, P. Nicolas, L. Collet, and P. Nordmann. 2005. Nosocomial spread of Pseudomonas aeruginosa isolates expressing the metallo-ß-lactamase VIM-2 in a hematology unit of a French hospital. Microb. Drug Resist. 11:254-259. [PubMed]
5. Bogaerts, P., C. Bauraing, A. Deplano, and Y. Glupczynski. 2007. Emergence and dissemination of BEL-1-producing Pseudomonas aeruginosa isolates in Belgium. Antimicrob. Agents Chemother. 51:1584-1585. [PMC free article] [PubMed]
6. Cantón, R., M. I. Morosini, O. M. de la Maza, and E. G. de la Pedrosa. 2008. IRT and CMT ß-lactamases and inhibitor resistance. Clin. Microbiol. Infect. 14(Suppl. 1):53-62. [PubMed]
7. Castanheira, M., R. E. Mendes, T. R. Walsh, A. C. Gales, and R. N. Jones. 2004. Emergence of the extended-spectrum ß-lactamase GES-1 in a Pseudomonas aeruginosa strain from Brazil: report from the SENTRY antimicrobial surveillance program. Antimicrob. Agents Chemother. 48:2344-2345. [PMC free article] [PubMed]
8. Celenza, G., C. Pellegrini, M. Caccamo, B. Segatore, G. Amicosante, and M. Perilli. 2006. Spread of blaCTX-M-type and blaPER-2 beta-lactamase genes in clinical isolates from Bolivian hospitals. J. Antimicrob. Chemother. 57:975-978. [PubMed]
9. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; 18th informational supplement M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Dubois, V., L. Poirel, C. Marie, C. Arpin, P. Nordmann, and C. Quentin. 2002. Molecular characterization of a novel class 1 integron containing blaGES-1 and a fused product of aac3-Ib/aac6-Ib″ gene cassettes in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 46:638-645. [PMC free article] [PubMed]
11. Empel, J., K. Filczak, A. Mrówka, W. Hryniewicz, D. M. Livermore, and M. Gniadkowski. 2007. Outbreak of Pseudomonas aeruginosa infections with PER-1 extended-spectrum beta-lactamase in Warsaw, Poland: further evidence for an international clonal complex. J. Clin. Microbiol. 45:2829-2834. [PMC free article] [PubMed]
12. Girlich, D., T. Naas, A. Leelaporn, L. Poirel, M. Fennewald, and P. Nordmann. 2002. Nosocomial spread of the integron-located veb-1-like cassette encoding an extended-spectrum ß-lactamase in Pseudomonas aeruginosa in Thailand. Clin. Infect. Dis. 34:175-182. [PubMed]
13. Gniadkowski, M. 2008. Evolution of extended-spectrum ß-lactamases by mutation. Clin. Microbiol. Infect. 14(Suppl. 1):11-32. [PubMed]
14. Kieser, T. 1984. Factors affecting the isolation of CCC DNA from Streptomyces lividans and Escherichia coli. Plasmid 12:19-36. [PubMed]
15. Kolayli, F., G. Gacar, A. Karadenizli, A. Sanic, H. Vahaboglu, and the Study Group. 2005. PER-1 is still widespread in Turkish hospitals among Pseudomonas aeruginosa and Acinetobacter spp. FEMS Microbiol. Lett. 249:241-245. [PubMed]
16. Labuschagne, C. J., G. F. Weldhagen, M. M. Ehlers, and M. G. Dove. 2008. Emergence of class 1 integron-associated GES-5 and GES-5-like extended-spectrum ß-lactamases in clinical isolates of Pseudomonas aeruginosa in South Africa. Int. J. Antimicrob. Agents 31:527-530. [PubMed]
17. Libisch, B., L. Poirel, Z. Lepsanovic, V. Mirovic, B. Balogh, J. Pászti, Z. Hunyadi, A. Dobák, M. Füzi, and P. Nordmann. 2008. Identification of PER-1 extended-spectrum ß-lactamase producing Pseudomonas aeruginosa clinical isolates of the international clonal complex CC11 from Hungary and Serbia. FEMS Immunol. Med. Microbiol. 54:330-338. [PubMed]
18. Mammeri, H., L. Poirel, and P. Nordmann. 2003. In vivo selection of a chromosomally encoded β-lactamase variant conferring ceftazidime resistance in Klebsiella oxytoca. Antimicrob. Agents Chemother. 47:3739-3742. [PMC free article] [PubMed]
19. Naas, T., L. Philippon, L. Poirel, E. Ronco, and P. Nordmann. 1999. An SHV-derived extended-spectrum ß-lactamase in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43:1281-1284. [PMC free article] [PubMed]
20. Naas, T., L. Poirel, and P. Nordmann. 2008. Minor extended-spectrum ß-lactamases. Clin. Microbiol. Infect. 14(Suppl. 1):42-52. [PubMed]
21. Pagani, L., E. Mantengoli, R. Migliavacca, E. Nucleo, S. Pollini, M. Spalla, R. Daturi, E. Romero, and G. M. Rossolini. 2004. Multifocal detection of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum ß-lactamase in Northern Italy. J. Clin. Microbiol. 42:2523-2529. [PMC free article] [PubMed]
22. Picão, R. C., L. Poirel, A. C. Gales, and P. Nordmann. 2009. Further identification of CTX-M-2 extended-spectrum ß-lactamase in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:2225-2226. [PMC free article] [PubMed]
23. Picão, R. C., L. Poirel, A. C. Gales, and P. Nordmann. 2009. Diversity of ß-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil. Antimicrob. Agents Chemother. 53:3908-3913. [PMC free article] [PubMed]
24. Poirel, L., L. Brinas, A. Verlinde, L. Ide, and P. Nordmann. 2005. BEL-1, a novel clavulanic acid-inhibited extended-spectrum ß-lactamase, and the class 1 integron In120 in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:3743-3748. [PMC free article] [PubMed]
25. Poirel, L., M. Guibert, S. Bellais, T. Naas, and P. Nordmann. 1999. Integron- and carbenicillinase-mediated reduced susceptibility to amoxicillin-clavulanic acid in isolates of multidrug-resistant Salmonella enterica serotype Typhimurium DT104 from French patients. Antimicrob. Agents Chemother. 43:1098-1104. [PMC free article] [PubMed]
26. Poirel, L., T. Naas, I. Le Thomas, A. Karim, E. Bingen, and P. Nordmann. 2001. CTX-M-type extended-spectrum ß-lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop. Antimicrob. Agents Chemother. 45:3355-3361. [PMC free article] [PubMed]
27. Poirel, L., G. F. Weldhagen, C. De Champs, and P. Nordmann. 2002. A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum ß-lactamase GES-2 in South Africa. J. Antimicrob. Chemother. 49:561-565. [PubMed]
28. Poirel, L., G. F. Weldhagen, T. Naas, C. De Champs, M. G. Dove, and P. Nordmann. 2001. GES-2, a class A ß-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem. Antimicrob. Agents Chemother. 45:2598-2603. [PMC free article] [PubMed]
29. Weldhagen, G. F. 2004. Rapid detection and sequence-specific differentiation of extended-spectrum ß-lactamase GES-2 from Pseudomonas aeruginosa by use of a real-time PCR assay. Antimicrob. Agents Chemother. 48:4059-4062. [PMC free article] [PubMed]
30. Weldhagen, G. F., L. Poirel, and P. Nordmann. 2003. Ambler class A extended-spectrum ß-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob. Agents Chemother. 47:2385-2392. [PMC free article] [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)